TCON Stock Overview
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
TRACON Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.43 |
52 Week High | US$2.19 |
52 Week Low | US$0.13 |
Beta | 0.79 |
1 Month Change | 158.88% |
3 Month Change | 134.97% |
1 Year Change | -76.24% |
3 Year Change | -94.47% |
5 Year Change | -97.47% |
Change since IPO | -99.54% |
Recent News & Updates
Recent updates
Tracon Pharmaceuticals announces $35M non-dilutive debt facility
Sep 06Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma
Aug 29Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M
Aug 10TRACON Pharmaceuticals announces $5M registered direct offering
Dec 29TRACON Pharma launches $8.8M direct offering
Dec 22Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study
Dec 10Tracon Pharma files China application for envafolimab in solid tumors
Nov 16Shareholder Returns
TCON | US Biotechs | US Market | |
---|---|---|---|
7D | 10.4% | -0.5% | 0.6% |
1Y | -76.2% | 9.6% | 29.5% |
Return vs Industry: TCON underperformed the US Biotechs industry which returned 10.2% over the past year.
Return vs Market: TCON underperformed the US Market which returned 29.8% over the past year.
Price Volatility
TCON volatility | |
---|---|
TCON Average Weekly Movement | 25.7% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TCON's share price has been volatile over the past 3 months.
Volatility Over Time: TCON's weekly volatility has increased from 21% to 26% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 17 | Charles Theuer | https://www.traconpharma.com |
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company’s clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors.
TRACON Pharmaceuticals, Inc. Fundamentals Summary
TCON fundamental statistics | |
---|---|
Market cap | US$20.93m |
Earnings (TTM) | -US$3.59m |
Revenue (TTM) | US$12.05m |
1.6x
P/S Ratio-5.5x
P/E RatioIs TCON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TCON income statement (TTM) | |
---|---|
Revenue | US$12.05m |
Cost of Revenue | US$12.28m |
Gross Profit | -US$232.00k |
Other Expenses | US$3.36m |
Earnings | -US$3.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.079 |
Gross Margin | -1.93% |
Net Profit Margin | -29.79% |
Debt/Equity Ratio | 0% |
How did TCON perform over the long term?
See historical performance and comparison